重度气喘的标靶治疗(生物製剂):NPS+(美国)
市场调查报告书
商品编码
1684123

重度气喘的标靶治疗(生物製剂):NPS+(美国)

NPS+ (US) - Targeted Therapies in Severe Asthma (Biologics)

出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

美国的过敏症专家和肺病专家在治疗气喘方面有多种选择。其中一些选项显然比其他选项具有更高的忠诚度和满意度,但为什么呢?本报告概述了影响医生选择的关键因素、各主要品牌与竞争药物的比较以及对美国领先气喘药物的见解。

报告内容

  • 依品牌比较 NPS 分数
  • 医师对特定品牌的忠诚度如何?
  • 能引起医师共鸣的品牌讯息
  • 影响医师选择的主要因素
  • 主要品牌的市场占有率
  • 主要品牌与竞争对手的比较
  • 因品牌满意度低而容易转换的品牌

主要品牌

  • Fasenra
  • Nucala
  • Dupixent
  • Tezspire
  • Cinqair
  • Xolair
简介目录

There are various options available to US allergists and pulmonologists treating asthma. Clearly, some of these options achieve greater levels of loyalty and satisfaction than others, but why? What are the key factors driving physician choice, and how does each of the leading brands compare to its competitors? Gain insights into leading asthma therapies in the US.

Key Questions Answered:

  • 1. How do NPS scores by brand compare?
  • 2. How loyal are physicians to specific brands?
  • 3. What brand messages resonate with physicians?
  • 4. What are the key factors driving physician choice?
  • 5. What is the market share of leading brands?
  • 6. How does each of the leading brands compare to its competitors?
  • 7. Which brands are vulnerable to switching due to low brand satisfaction?

Key Brands

  • Fasenra
  • Nucala
  • Dupixent
  • Tezspire
  • Cinqair
  • Xolair

Methodology

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.